Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2011 (2011), Article ID 320571, 17 pages
http://dx.doi.org/10.1155/2011/320571
Review Article

T Cells and Adoptive Immunotherapy: Recent Developments and Future Prospects in Gastrointestinal Oncology

1Department of Internal Medicine, University of Florence, Viale Morgagni 85, 50134 Florence, Italy
2Dipartimento Biomedicina, Azienda Ospedaliera Universitaria Careggi, Viale Morgagni 85, 50134 Florence, Italy

Received 1 July 2011; Accepted 24 August 2011

Academic Editor: Clelia M. Riera

Copyright © 2011 Amedeo Amedei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Garcia, A. Jemal, E. M. Ward et al., “Global Cancer Facts & Figures 2007,” American Cancer Society, http://www.cancer.org.
  2. S. Raimondi, P. Maisonneuve, and A. B. Lowenfels, “Epidemiology of pancreatic cancer: an overview,” Nature Reviews Gastroenterology and Hepatology, vol. 6, no. 12, pp. 699–708, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. American Cancer Society, “Cancer Facts & Figures,” American Cancer Society, 2010, http://www.cancer.org/Research/CancerFactsFigures/index.
  4. J. M. Winter, J. L. Cameron, K. A. Campbell et al., “1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience,” Journal of Gastrointestinal Surgery, vol. 10, no. 9, pp. 1199–1210, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Saka, S. Morita, T. Fukagawa, and H. Katai, “Present and future status of gastric cancer surgery,” Japanese Journal of Clinical Oncology, vol. 41, no. 3, pp. 307–313, 2011. View at Publisher · View at Google Scholar
  6. F. Giuliani, F. de Vita, G. Colucci, and S. Pisconti, “Maintenance therapy in colon cancer,” Cancer Treatment Reviews, vol. 36, supplement 3, pp. S42–S45, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Cunningham, W. H. Allum, S. P. Stenning et al., “MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer,” The New England Journal of Medicine, vol. 355, no. 1, pp. 11–20, 2006. View at Publisher · View at Google Scholar
  8. D. V. T. Catenacci, M. Kozloff, H. L. Kindler, and B. Polite, “Personalized colon cancer care in 2010,” Seminars in Oncology, vol. 38, no. 2, pp. 284–308, 2011. View at Publisher · View at Google Scholar
  9. A. Artinyan, D. A. Anaya, S. McKenzie, J. D. I. Ellenhorn, and J. Kim, “Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma,” Cancer, vol. 117, no. 10, pp. 2044–2049, 2011. View at Publisher · View at Google Scholar
  10. Y. Touchefeu, K. J. Harrington, J. P. Galmiche, and G. Vassaux, “Review article: gene therapy, recent developments and future prospects in gastrointestinal oncology,” Alimentary Pharmacology and Therapeutics, vol. 32, no. 8, pp. 953–968, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Amedei, E. Niccolai, C. D. Bella et al., “Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma,” Cancer Immunology, Immunotherapy, vol. 58, no. 11, pp. 1819–1830, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Gaudernack, “Prospects for vaccine therapy for pancreatic cancer,” Best Practice and Research: Clinical Gastroenterology, vol. 20, no. 2, pp. 299–314, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Iovino, S. Meraviglia, M. Spina et al., “Immunotherapy targeting colon cancer stem cells,” Immunotherapy, vol. 3, no. 1, pp. 97–106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. J. Goedert, “The epidemiology of acquired immunodeficiency syndrome malignancies,” Seminars in Oncology, vol. 27, no. 4, pp. 390–401, 2000. View at Google Scholar · View at Scopus
  15. G. B. Challis and H. J. Stam, “The spontaneous regression of cancer. A review of cases from 1900 to 1987,” Acta Oncologica, vol. 29, no. 5, pp. 545–550, 1990. View at Google Scholar · View at Scopus
  16. L. Zhang, J. R. Conejo-Garcia, D. Katsaros et al., “Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer,” The New England Journal of Medicine, vol. 348, no. 3, pp. 203–213, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Nagorsen, C. Scheibenbogen, F. M. Marincola, A. Letsch, and U. Keilholz, “Natural T cell immunity against cancer,” Clinical Cancer Research, vol. 9, no. 12, pp. 4296–4303, 2003. View at Google Scholar · View at Scopus
  18. S. E. Erdman and T. Poutahidis, “Roles for inflammation and regulatory T cells in colon cancer,” Toxicologic Pathology, vol. 38, no. 1, pp. 76–87, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Yokokawa, C. Palena, P. Arlen et al., “Identification of novel human CTL epitopes and their agonist epitopes of mesothelin,” Clinical Cancer Research, vol. 11, no. 17, pp. 6342–6351, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. M. H. Andersen, L. O. Pedersen, J. C. Becket, and P. T. Straten, “Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients,” Cancer Research, vol. 61, no. 3, pp. 869–872, 2001. View at Google Scholar · View at Scopus
  21. F. M. Johnston, M. C. B. Tan, B. R. Tan Jr. et al., “Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer,” Clinical Cancer Research, vol. 15, no. 21, pp. 6511–6518, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Kotera, J. D. Fontenot, G. Pecher, R. S. Metzgar, and O. J. Finn, “Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients,” Cancer Research, vol. 54, no. 11, pp. 2856–2860, 1994. View at Google Scholar · View at Scopus
  23. B. Kubuschok, F. Neumann, R. Breit et al., “Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer,” Clinical Cancer Research, vol. 12, no. 4, pp. 1365–1372, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Wenandy, R. B. Sørensen, L. Sengeløv, I. M. Svane, P. T. Straten, and M. H. Andersen, “The immunogenicity of the hTERT540-548 peptide in cancer,” Clinical Cancer Research, vol. 14, no. 1, pp. 4–7, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. H. Yanagimoto, T. Mine, K. Yamamoto et al., “Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer,” Cancer Science, vol. 98, no. 4, pp. 605–611, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Kubuschok, X. Xie, R. Jesnowski et al., “Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis,” International Journal of Cancer, vol. 109, no. 4, pp. 568–575, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. F. H. Schmitz-Winnenthal, C. Volk, K. Z'Graggen et al., “High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients,” Cancer Research, vol. 65, no. 21, pp. 10079–10087, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. F. H. Schmitz-Winnenthal, L. V. G. Escobedo, P. Beckhove et al., “Specific immune recognition of pancreatic carcinoma by patient-derived CD4 and CD8 T cells and its improvement by interferon-γ,” International Journal of Oncology, vol. 28, no. 6, pp. 1419–1428, 2006. View at Google Scholar · View at Scopus
  29. C. Choi, M. Witzens, M. Bucur et al., “Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma,” Blood, vol. 105, no. 5, pp. 2132–2134, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Feuerer, P. Beckhove, L. Bai et al., “Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow,” Nature Medicine, vol. 7, no. 4, pp. 452–458, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Müller-Berghaus, K. Ehlert, S. Ugurel et al., “Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration,” Cancer Research, vol. 66, no. 12, pp. 5997–6001, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. I. Esposito, M. Menicagli, N. Funel et al., “Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma,” Journal of Clinical Pathology, vol. 57, no. 6, pp. 630–636, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Jesnowski, D. Fürst, J. Ringel et al., “Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine,” Laboratory Investigation, vol. 85, no. 10, pp. 1276–1291, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Feuerer, P. Beckhove, N. Garbi et al., “Bone marrow as a priming site for T-cell responses to blood-borne antigen,” Nature Medicine, vol. 9, no. 9, pp. 1151–1157, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Fukunaga, M. Miyamoto, Y. Cho et al., “CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma,” Pancreas, vol. 28, no. 1, pp. e26–e31, 2004. View at Google Scholar · View at Scopus
  36. N. Hiraoka, K. Onozato, T. Kosuge, and S. Hirohashi, “Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions,” Clinical Cancer Research, vol. 12, no. 18, pp. 5423–5434, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. W. von Bernstorff, M. Voss, S. Freichel et al., “Systemic and local immunosuppression in pancreatic cancer patients,” Clinical Cancer Research, vol. 7, no. 3, pp. 925s–932s, 2001. View at Google Scholar · View at Scopus
  38. W. V. Bernstorff, R. A. Spanjaard, A. K. Chan et al., “Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand,” Surgery, vol. 125, no. 1, pp. 73–84, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. L. De Monte, M. Reni, E. Tassi et al., “Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer,” Journal of Experimental Medicine, vol. 208, no. 3, pp. 469–478, 2011. View at Publisher · View at Google Scholar
  40. C. E. Clark, G. L. Beatty, and R. H. Vonderheide, “Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer,” Cancer Letters, vol. 279, no. 1, pp. 1–7, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Fong and E. J. Small, “Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment,” Journal of Clinical Oncology, vol. 26, no. 32, pp. 5275–5283, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. C. M. Paulos and C. H. June, “Putting the brakes on BTLA in T cell-mediated cancer immunotherapy,” Journal of Clinical Investigation, vol. 120, no. 1, pp. 76–80, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. M. K. Gjertsen, A. Bakka, J. Breivik et al., “Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation,” The Lancet, vol. 346, no. 8987, pp. 1399–1400, 1995. View at Google Scholar · View at Scopus
  44. M. K. Gjertsen, J. Bjørheim, I. Saeterdal, J. Myklebust, and G. Gaudernack, “Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation,” International Journal of Cancer, vol. 72, no. 5, pp. 784–790, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. M. K. Gjertsen, T. Buanes, A. R. Rosseland et al., “Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma,” International Journal of Cancer, vol. 92, no. 3, pp. 441–450, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. C. F. Hung, Y. C. Tsai, L. He, and T. C. Wu, “Control of mesothelin-expressing ovarian cancer using adoptive transfer of mesothelin peptide-specific CD8+ T cells,” Gene Therapy, vol. 14, no. 12, pp. 921–929, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Kawaoka, M. Oka, M. Takashima et al., “Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1 -expressing human pancreatic cancer cell line YPK-1,” Oncology Reports, vol. 20, no. 1, pp. 155–163, 2008. View at Google Scholar · View at Scopus
  48. H. Kondo, S. Hazama, T. Kawaoka et al., “Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes,” Anticancer Research, vol. 28, no. 1, pp. 379–387, 2008. View at Google Scholar · View at Scopus
  49. P. Cappello, B. Tomaino, R. Chiarle et al., “An integrated humoral and cellular response is elicited in pancreatic cancer by α-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen,” International Journal of Cancer, vol. 125, no. 3, pp. 639–648, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Sato, Y. Nabeta, H. Kondo et al., “Human CD8 and CD4 T cell epitopes of epithelial cancer antigens,” Cancer Chemotherapy and Pharmacology, vol. 46, pp. S86–S90, 2000. View at Google Scholar · View at Scopus
  51. H. Kondo, H. Sahara, A. Miyazaki et al., “Natural antigenic peptides from squamous cell carcinoma recognized by autologous HLA-DR8-restricted CD4+ T cells,” Japanese Journal of Cancer Research, vol. 93, no. 8, pp. 917–924, 2002. View at Google Scholar · View at Scopus
  52. N. Y. Shih, H. L. Lai, G. C. Chang et al., “Anti-α-enolase autoantibodies are down-regulated in advanced cancer patients,” Japanese Journal of Clinical Oncology, vol. 40, no. 7, Article ID hyq028, pp. 663–669, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. S. H. Tu, C. C. Chang, C. S. Chen et al., “Increased expression of enolase α in human breast cancer confers tamoxifen resistance in human breast cancer cells,” Breast Cancer Research and Treatment, vol. 121, no. 3, pp. 539–553, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. G. C. Chang, K. J. Liu, C. L. Hsieh et al., “Identification of α-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes,” Clinical Cancer Research, vol. 12, no. 19, pp. 5746–5754, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. “Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994,” IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 61, pp. 1–241, 1994.
  56. J. B. A. Crusius, F. Canzian, G. Capellá et al., “Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST),” Annals of Oncology, vol. 19, no. 11, pp. 1894–1902, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. C. A. González, N. Sala, and G. Capellá, “Genetic susceptibility and gastric cancer risk,” International Journal of Cancer, vol. 100, no. 3, pp. 249–260, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Hamajima, M. Naito, T. Kondo, and Y. Goto, “Genetic factors involved in the development of Helicobacter pylori-related gastric cancer,” Cancer Science, vol. 97, no. 11, pp. 1129–1138, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Hou, E. M. El-Omar, J. Chen et al., “Polymorphisms in Th1-type cell-mediated response genes and risk of gastric cancer,” Carcinogenesis, vol. 28, no. 1, pp. 118–123, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Starzyńska, K. Ferenc, T. Wex et al., “The association between the interleukin-1 polymorphisms and gastric cancer risk depends on the family history of gastric carcinoma in the study population,” American Journal of Gastroenterology, vol. 101, no. 2, pp. 248–254, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Ben-Baruch, “Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators,” Seminars in Cancer Biology, vol. 16, no. 1, pp. 38–52, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. W. W. Lin and M. Karin, “A cytokine-mediated link between innate immunity, inflammation, and cancer,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1175–1183, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. R. Kim, M. Emi, K. Tanabe, and K. Arihiro, “Tumor-driven evolution of immunosuppressive networks during malignant progression,” Cancer Research, vol. 66, no. 11, pp. 5527–5536, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. H. E. Lee, S. W. Chae, Y. J. Lee et al., “Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer,” British Journal of Cancer, vol. 99, no. 10, pp. 1704–1711, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. Z. Ren, G. Pang, R. Clancy et al., “Shift of the gastric T-cell response in gastric carcinoma,” Journal of Gastroenterology and Hepatology, vol. 16, no. 2, pp. 142–148, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. M. M. D'Elios, A. Amedei, and G. D. Prete, “Helicobacter pylori antigen-specific T-cell responses at gastric level in chronic gastritis, peptic ulcer, gastric cancer and low-grade mucosa-associated lymphoid tissue (MALT) lymphoma,” Microbes and Infection, vol. 5, no. 8, pp. 723–730, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. T. Maruyama, K. Kono, Y. Mizukami et al., “Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer,” Cancer Science, vol. 101, no. 9, pp. 1947–1954, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. C. H. June, “Principles of adoptive T cell cancer therapy,” Journal of Clinical Investigation, vol. 117, no. 5, pp. 1204–1212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. C. Yee, J. A. Thompson, D. Byrd et al., “Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 25, pp. 16168–16173, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. J. Kim, J. Lim, J. S. Kang et al., “Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells,” Archives of Pharmacal Research, vol. 33, no. 11, pp. 1789–1795, 2010. View at Publisher · View at Google Scholar
  71. Y. Wu, L. Wang, and Y. Zhang, “Dendritic cells as vectors for immunotherapy of tumor and its application for gastric cancer therapy,” Cellular & Molecular Immunology., vol. 1, no. 5, pp. 351–356, 2004. View at Google Scholar · View at Scopus
  72. T. Hoshino, N. Seki, M. Kikuchi et al., “HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer,” International Journal of Cancer, vol. 70, no. 6, pp. 631–638, 1997. View at Publisher · View at Google Scholar · View at Scopus
  73. K. Kono, Y. Rongcun, J. Charo et al., “Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes,” International Journal of Cancer, vol. 78, no. 2, pp. 202–208, 1998. View at Publisher · View at Google Scholar · View at Scopus
  74. D. L. Guo, M. Dong, L. Wang, L. P. Sun, and Y. Yuan, “Expression of gastric cancer-associated MG7 antigen in gastric cancer, precancerous lesions and H. pylori-associated gastric diseases,” World Journal of Gastroenterology, vol. 8, no. 6, pp. 1009–1013, 2002. View at Google Scholar · View at Scopus
  75. K. Wu, Y. Nie, C. Guo, Y. Chen, J. Ding, and D. Fan, “Molecular basis of therapeutic approaches to gastric cancer,” Journal of Gastroenterology and Hepatology, vol. 24, no. 1, pp. 37–41, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. Y. Nie, K. Wu, J. Yang et al., “Induction of T lymphocytes specific to human gastric cancer using HLA-A matched allogeneic gastric tumor cells,” Journal of Immunotherapy, vol. 26, no. 5, pp. 403–411, 2003. View at Publisher · View at Google Scholar · View at Scopus
  77. J. Jiang, N. Xu, C. Wu et al., “Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells,” Anticancer Research, vol. 26, no. 3, pp. 2237–2242, 2006. View at Google Scholar · View at Scopus
  78. C. Wu, J. Jiang, L. Shi, and N. Xu, “Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer,” Anticancer Research, vol. 28, no. 6, pp. 3997–4002, 2008. View at Google Scholar · View at Scopus
  79. S. Sun, X. M. Li, X. D. Li, and W. S. Yang, “Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines,” Cancer Biotherapy and Radiopharmaceuticals, vol. 20, no. 2, pp. 173–180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. R. B. Alexander and S. A. Rosenberg, “Long term survival of adoptively transferred tumor-infiltrating lymphocytes in mice,” Journal of Immunology, vol. 145, no. 5, pp. 1615–1620, 1990. View at Google Scholar · View at Scopus
  81. K. Kono, A. Takahashi, F. Ichihara et al., “Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial,” Clinical Cancer Research, vol. 8, no. 6, pp. 1767–1771, 2002. View at Google Scholar · View at Scopus
  82. S. A. Rosenberg, J. R. Yannelli, J. C. Yang et al., “Treatment of patients with metastatic melanoma with autologous tumor- infiltrating lymphocytes and interleukin 2,” Journal of the National Cancer Institute, vol. 86, no. 15, pp. 1159–1166, 1994. View at Google Scholar · View at Scopus
  83. M. E. Dudley, J. R. Wunderlich, T. E. Shelton, J. Even, and S. A. Rosenberg, “Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients,” Journal of Immunotherapy, vol. 26, no. 4, pp. 332–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Tomšová, B. Melichar, I. Sedláková, and I. Šteiner, “Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma,” Gynecologic Oncology, vol. 108, no. 2, pp. 415–420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. J. Galon, A. Costes, F. Sanchez-Cabo et al., “Type, density, and location of immune cells within human colorectal tumors predict clinical outcome,” Science, vol. 313, no. 5795, pp. 1960–1964, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. F. Pagès, A. Berger, M. Camus et al., “Effector memory T cells, early metastasis, and survival in colorectal cancer,” The New England Journal of Medicine, vol. 353, no. 25, pp. 2654–2666, 2005. View at Publisher · View at Google Scholar · View at Scopus
  87. P. Salama, M. Phillips, F. Grieu et al., “Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 2, pp. 186–192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. Y. Schwitalle, M. Kloor, S. Eiermann et al., “Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers,” Gastroenterology, vol. 134, no. 4, pp. 988–997, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. D. Tougeron, E. Fauquembergue, A. Rouquette et al., “Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations,” Modern Pathology, vol. 22, no. 9, pp. 1186–1195, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. M. L. Disis, H. Bernhard, and E. M. Jaffee, “Use of tumour-responsive T cells as cancer treatment,” The Lancet, vol. 373, no. 9664, pp. 673–683, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Shia, N. A. Ellis, P. B. Paty et al., “Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer,” American Journal of Surgical Pathology, vol. 27, no. 11, pp. 1407–1417, 2003. View at Publisher · View at Google Scholar · View at Scopus
  92. M. A. Jenkins, S. Hayashi, A. M. O'Shea et al., “Pathology features in bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study,” Gastroenterology, vol. 133, no. 1, pp. 48–56, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. S. Ogino, K. Nosho, N. Irahara et al., “Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype,” Clinical Cancer Research, vol. 15, no. 20, pp. 6412–6420, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. F. M. Speetjens, M. M. Lauwen, K. L. Franken et al., “Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer,” International Journal of Cancer, vol. 123, no. 4, pp. 838–845, 2008. View at Publisher · View at Google Scholar · View at Scopus
  95. S. Popat, R. Hubner, and R. S. Houlston, “Systematic review of microsatellite instability and colorectal cancer prognosis,” Journal of Clinical Oncology, vol. 23, no. 3, pp. 609–618, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. S. Ogino, K. Nosho, G. J. Kirkner et al., “CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer,” Gut, vol. 58, no. 1, pp. 90–96, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. W. S. Samowitz, C. Sweeney, J. Herrick et al., “Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers,” Cancer Research, vol. 65, no. 14, pp. 6063–6069, 2005. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Ogino, K. Nosho, G. J. Kirkner et al., “PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer,” Journal of Clinical Oncology, vol. 27, no. 9, pp. 1477–1484, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. S. Ogino, K. Nosho, G. J. Kirkner et al., “A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer,” Journal of the National Cancer Institute, vol. 100, no. 23, pp. 1734–1738, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. K. Nosho, Y. Baba, N. Tanaka et al., “Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review,” Journal of Pathology, vol. 222, no. 4, pp. 350–366, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. D. Nagorsen, S. Voigt, E. Berg, H. Stein, E. Thiel, and C. Loddenkemper, “Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival,” Journal of Translational Medicine, vol. 5, p. 62, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. S. Yaqub, K. Henjum, M. Mahic et al., “Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner,” Cancer Immunology, Immunotherapy, vol. 57, no. 6, pp. 813–821, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. S. L. Clarke, G. J. Betts, A. Plant et al., “CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer,” PLoS ONE, vol. 1, no. 1, p. e129, 2006. View at Publisher · View at Google Scholar · View at Scopus
  104. A. Bonertz, J. Weitz, D. H. K. Pietsch et al., “Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma,” Journal of Clinical Investigation, vol. 119, no. 11, pp. 3311–3321, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. M. Bueter, M. Gasser, N. Schramm et al., “T-cell response to p53 tumor-associated antigen in patients with colorectal carcinoma,” International Journal of Oncology, vol. 28, no. 2, pp. 431–438, 2006. View at Google Scholar · View at Scopus
  106. G. Filaci, D. Fenoglio, M. Fravega et al., “CD8+CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers,” Journal of Immunology, vol. 179, no. 7, pp. 4323–4334, 2007. View at Google Scholar · View at Scopus
  107. N. Chaput, S. Louafi, A. Bardier et al., “Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue,” Gut, vol. 58, no. 4, pp. 520–529, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. S. Makita, T. Kanai, S. Oshima et al., “CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells,” Journal of Immunology, vol. 173, no. 5, pp. 3119–3130, 2004. View at Google Scholar · View at Scopus
  109. S. Yang, B. Wang, C. Guan et al., “Foxp3+IL-17+ T cells promote development of cancer-initiating cells in colorectal cancer,” Journal of Leukocyte Biology, vol. 89, no. 1, pp. 85–91, 2010. View at Publisher · View at Google Scholar
  110. S. A. Rosenberg, B. S. Packard, P. M. Aebersold et al., “Use of tumor-infiltrating lymphocyts and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report,” The New England Journal of Medicine, vol. 319, no. 25, pp. 1676–1680, 1988. View at Google Scholar · View at Scopus
  111. M. E. Dudley, J. R. Wunderlich, P. F. Robbins et al., “Cancer regression and autoimmunity in patients following clonal repopulation with anti-tumor lymphocytes,” Science, vol. 298, no. 5594, pp. 850–854, 2002. View at Publisher · View at Google Scholar
  112. M. E. Dudley, J. R. Wunderlich, J. C. Yang et al., “Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma,” Journal of Clinical Oncology, vol. 23, no. 10, pp. 2346–2357, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. R. A. Morgan, M. E. Dudley, J. R. Wunderlich et al., “Cancer regression in patients after transfer of genetically engineered lymphocytes,” Science, vol. 314, no. 5796, pp. 126–129, 2006. View at Publisher · View at Google Scholar · View at Scopus
  114. S. A. Rosenberg, J. C. Yang, and N. P. Restifo, “Cancer immunotherapy: moving beyond current vaccines,” Nature Medicine, vol. 10, no. 9, pp. 909–915, 2004. View at Publisher · View at Google Scholar · View at Scopus
  115. F. Ossendorp, E. Mengedé, M. Camps, R. Filius, and C. J. M. Melief, “Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors,” Journal of Experimental Medicine, vol. 187, no. 5, pp. 693–702, 1998. View at Publisher · View at Google Scholar · View at Scopus
  116. K. Hung, R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, and H. Levitsky, “The central role of CD4+ T cells in the antitumor immune response,” Journal of Experimental Medicine, vol. 188, no. 12, pp. 2357–2368, 1998. View at Publisher · View at Google Scholar · View at Scopus
  117. P. Muranski and N. P. Restifo, “Adoptive immunotherapy of cancer using CD4+ T cells,” Current Opinion in Immunology, vol. 21, no. 2, pp. 200–208, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. J. P. Ridge, F. di Rosa, and P. Matzinger, “A conditioned dendritic cell can be a temporal bridge between a CD4 + T-helper and a T-killer cell,” Nature, vol. 393, no. 6684, pp. 474–478, 1998. View at Google Scholar · View at Scopus
  119. E. M. Janssen, N. M. Droin, E. E. Lemmens et al., “CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death,” Nature, vol. 434, no. 7029, pp. 88–93, 2005. View at Publisher · View at Google Scholar · View at Scopus
  120. S. R. M. Bennett, F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. A. P. Miller, and W. R. Heath, “Help for cytotoxic-T-cell responses is mediated by CD4O signalling,” Nature, vol. 393, no. 6684, pp. 478–480, 1998. View at Google Scholar · View at Scopus
  121. S. P. Schoenberger, R. E. M. Toes, E. I. H. van der Voort, R. Offringa, and C. J. M. Melief, “T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD4OL interactions,” Nature, vol. 393, no. 6684, pp. 480–483, 1998. View at Google Scholar · View at Scopus
  122. S. A. Rosenberg, N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley, “Adoptive cell transfer: a clinical path to effective cancer immunotherapy,” Nature Reviews Cancer, vol. 8, no. 4, pp. 299–308, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. P. A. Antony, C. A. Piccirillo, A. Akpinarli et al., “CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells,” Journal of Immunology, vol. 174, no. 5, pp. 2591–2601, 2005. View at Google Scholar · View at Scopus
  124. R. S. Accolla, M. Jotterand-Bellomo, and L. Scarpellino, “aIr-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression,” Journal of Experimental Medicine, vol. 164, no. 1, pp. 369–374, 1986. View at Google Scholar · View at Scopus
  125. V. Steimle, L. A. Otten, M. Zufferey, and B. Mach, “Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome),” Cell, vol. 75, no. 1, pp. 135–146, 1993. View at Publisher · View at Google Scholar · View at Scopus
  126. R. Meazza, A. Comes, A. M. Orengo, S. Ferrini, and R. S. Accolla, “Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells,” European Journal of Immunology, vol. 33, no. 5, pp. 1183–1192, 2003. View at Publisher · View at Google Scholar · View at Scopus
  127. L. Mortara, P. Castellani, R. Meazza et al., “CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory,” Clinical Cancer Research, vol. 12, no. 11, pp. 3435–3443, 2006. View at Publisher · View at Google Scholar · View at Scopus
  128. L. Mortara, V. Frangione, P. Castellani, A. D. L. Barbaro, and R. S. Accolla, “Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions,” International Immunology, vol. 21, no. 6, pp. 655–665, 2009. View at Publisher · View at Google Scholar · View at Scopus
  129. V. Frangione, L. Mortara, P. Castellani, A. D. L. Barbaro, and R. S. Accolla, “CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy,” International Journal of Cancer, vol. 127, no. 7, pp. 1614–1624, 2010. View at Publisher · View at Google Scholar · View at Scopus
  130. J. Papailiou, K. J. Bramis, M. Gazouli, and G. Theodoropoulos, “Stem cells in colon cancer. A new era in cancer theory begins,” International Journal of Colorectal Disease, vol. 26, no. 1, pp. 1–11, 2011. View at Publisher · View at Google Scholar
  131. M. F. Clarke, J. E. Dick, P. B. Dirks et al., “Cancer stem cells—perspectives on current status and future directions: AACR workshop on cancer stem cells,” Cancer Research, vol. 66, no. 19, pp. 9339–9344, 2006. View at Publisher · View at Google Scholar · View at Scopus
  132. P. Dalerba, S. J. Dylla, I. K. Park et al., “Phenotypic characterization of human colorectal cancer stem cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 24, pp. 10158–10163, 2007. View at Publisher · View at Google Scholar · View at Scopus
  133. C. A. O'Brien, A. Pollett, S. Gallinger, and J. E. Dick, “A human colon cancer cell capable of initiating tumour growth in immunodeficient mice,” Nature, vol. 445, no. 7123, pp. 106–110, 2007. View at Publisher · View at Google Scholar · View at Scopus
  134. L. Ricci-Vitiani, D. G. Lombardi, E. Pilozzi et al., “Identification and expansion of human colon-cancer-initiating cells,” Nature, vol. 445, no. 7123, pp. 111–115, 2007. View at Publisher · View at Google Scholar · View at Scopus
  135. E. H. Huang, M. J. Hynes, T. Zhang et al., “Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis,” Cancer Research, vol. 69, no. 8, pp. 3382–3389, 2009. View at Publisher · View at Google Scholar · View at Scopus
  136. M. Dean, T. Fojo, and S. Bates, “Tumour stem cells and drug resistance,” Nature Reviews Cancer, vol. 5, no. 4, pp. 275–284, 2005. View at Publisher · View at Google Scholar · View at Scopus
  137. S. Inoda, Y. Hirohashi, T. Torigoe et al., “Cep55/c10orf3, a tumor antigen derived from a centrosome residing protein in breast carcinoma,” Journal of Immunotherapy, vol. 32, no. 5, pp. 474–485, 2009. View at Publisher · View at Google Scholar · View at Scopus
  138. S. Inoda, R. Morita, Y. Hirohashi et al., “The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma,” Experimental and Molecular Pathology, vol. 90, no. 1, pp. 55–60, 2011. View at Publisher · View at Google Scholar · View at Scopus
  139. Y. Naito, K. Saito, K. Shiiba et al., “CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer,” Cancer Research, vol. 58, no. 16, pp. 3491–3494, 1998. View at Google Scholar · View at Scopus
  140. M. Guidoboni, R. Gafà, A. Viel et al., “Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis,” American Journal of Pathology, vol. 159, no. 1, pp. 297–304, 2001. View at Google Scholar · View at Scopus
  141. Å. Öberg, S. Samii, R. Stenling, and G. Lindmark, “Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors,” International Journal of Colorectal Disease, vol. 17, no. 1, pp. 25–29, 2002. View at Publisher · View at Google Scholar
  142. J. K. Petty, K. He, C. L. Corless, J. T. Vetto, and A. D. Weinberg, “Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134),” American Journal of Surgery, vol. 183, no. 5, pp. 512–518, 2002. View at Publisher · View at Google Scholar · View at Scopus
  143. A. C. P. Diederichsen, J. V. B. Hjelmborg, P. B. Christensen, J. Zeuthen, and C. Fenge, “Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells,” Cancer Immunology, Immunotherapy, vol. 52, no. 7, pp. 423–428, 2003. View at Publisher · View at Google Scholar · View at Scopus
  144. Y. Funada, T. Noguchi, R. Kikuchi, S. Takeno, Y. Uchida, and H. E. Gabbert, “Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer,” Oncology Reports, vol. 10, no. 2, pp. 309–313, 2003. View at Google Scholar · View at Scopus
  145. F. Prall, T. Dührkop, V. Weirich et al., “Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability,” Human Pathology, vol. 35, no. 7, pp. 808–816, 2004. View at Publisher · View at Google Scholar
  146. A. G. Menon, C. M. Janssen-Van Rhijn, H. Morreau et al., “Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis,” Laboratory Investigation, vol. 84, no. 4, pp. 493–501, 2004. View at Publisher · View at Google Scholar
  147. T. Chiba, H. Ohtani, T. Mizoi et al., “Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis,” British Journal of Cancer, vol. 91, no. 9, pp. 1711–1717, 2004. View at Publisher · View at Google Scholar · View at Scopus
  148. F. Pagès, A. Berger, M. Camus et al., “Effector memory T cells, early metastasis, and survival in colorectal cancer,” The New England Journal of Medicine, vol. 353, no. 25, pp. 2654–2666, 2005. View at Publisher · View at Google Scholar
  149. C. I. M. Baeten, K. Castermans, H. F. P. Hillen, and A. W. Griffioen, “Proliferating endothelial cells and leukocyte infiltration as prognostic markers in colorectal cancer,” Clinical Gastroenterology and Hepatology, vol. 4, no. 11, pp. 1351–1357, 2006. View at Publisher · View at Google Scholar · View at Scopus
  150. J. Galon, A. Costes, F. Sanchez-Cabo et al., “Type, density, and location of immune cells within human colorectal tumors predict clinical outcome,” Science, vol. 313, no. 5795, pp. 1960–1964, 2006. View at Publisher · View at Google Scholar · View at Scopus
  151. I. Zlobec, P. Minoo, D. Baumhoer et al., “Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer,” Cancer, vol. 112, no. 3, pp. 495–502, 2008. View at Publisher · View at Google Scholar · View at Scopus
  152. I. Zlobec, K. Baker, L. Terracciano et al., “Two-marker protein profile predicts poor prognosis in patients with early rectal cancer,” British Journal of Cancer, vol. 99, no. 10, pp. 1712–1717, 2008. View at Publisher · View at Google Scholar · View at Scopus
  153. F. A. Sinicrope, R. L. Rego, S. M. Ansell, K. L. Knutson, N. R. Foster, and D. J. Sargent, “Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma,” Gastroenterology, vol. 137, no. 4, pp. 1270–1279, 2009. View at Publisher · View at Google Scholar · View at Scopus
  154. L. Laghi, P. Bianchi, E. Miranda et al., “CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study,” The Lancet Oncology, vol. 10, no. 9, pp. 877–884, 2009. View at Publisher · View at Google Scholar · View at Scopus
  155. D. M. Frey, R. A. Droeser, C. T. Viehl et al., “High frequency of tumor-infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients,” International Journal of Cancer, vol. 126, no. 11, pp. 2635–2643, 2010. View at Publisher · View at Google Scholar
  156. P. Salama, M. Phillips, F. Grieu et al., “Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 2, pp. 186–192, 2009. View at Publisher · View at Google Scholar · View at Scopus
  157. F. Pagès, A. Kirilovsky, B. Mlecnik et al., “In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer,” Journal of Clinical Oncology, vol. 27, no. 35, pp. 5944–5951, 2009. View at Publisher · View at Google Scholar
  158. V. Deschoolmeester, M. Baay, E. van Marck et al., “Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients,” BMC Immunology, vol. 11, p. 19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  159. H. Suzuki, N. Chikazawa, T. Tasaka et al., “Intratumoral CD8+ T/FOXP3+ cell ratio is a predictive marker for survival in patients with colorectal cancer,” Cancer Immunology, Immunotherapy, vol. 59, no. 5, pp. 653–661, 2010. View at Publisher · View at Google Scholar · View at Scopus
  160. P. Correale, M. S. Rotundo, M. T. del Vecchio et al., “Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy,” Journal of Immunotherapy, vol. 33, no. 4, pp. 435–441, 2010. View at Publisher · View at Google Scholar · View at Scopus
  161. W. S. Lee, S. Park, W. Y. Lee, S. H. Yun, and H. K. Chun, “Clinical impact of tumor-infiltrating lymphocytes for survival in stage II colon cancer,” Cancer, vol. 116, no. 22, pp. 5188–5199, 2010. View at Publisher · View at Google Scholar
  162. K. Nosho, Y. Baba, N. Tanaka et al., “Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review,” Journal of Pathology, vol. 222, no. 4, pp. 350–366, 2010. View at Publisher · View at Google Scholar · View at Scopus